KYMERA THERAPEUTICS, INC. Shareholders' Equity
KYMERA THERAPEUTICS, INC. (KYMR) had Shareholders' Equity of $1.51 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent $1.51B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $1.54B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $1.58B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $946.26M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $1.51B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $1.54B 10-Q · filed 2026-08-05 |
| 2025-12-31 | $1.58B 10-Q · filed 2026-08-05 |
| 2025-09-30 | $946.26M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $971.48M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $786.23M 10-Q · filed 2026-08-05 |
| 2024-12-31 | $835.62M 10-Q · filed 2026-08-05 |
| 2024-09-30 | $892.93M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $684.92M 10-Q · filed 2025-11-04 |
| 2024-03-31 | $711.20M 10-Q · filed 2025-08-11 |
| 2023-12-31 | $394.97M 10-K · filed 2026-02-26 |
| 2023-09-30 | $395.54M 10-Q · filed 2024-10-31 |
| 2023-06-30 | $435.43M 10-Q · filed 2024-10-31 |
| 2023-03-31 | $462.00M 10-Q · filed 2024-08-07 |
| 2022-12-31 | $490.15M 10-K · filed 2026-02-26 |
| 2022-09-30 | $512.88M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $397.95M 10-Q · filed 2023-11-02 |
| 2022-03-31 | $428.72M 10-Q · filed 2023-08-03 |
| 2021-12-31 | $459.64M 10-K · filed 2025-02-27 |
| 2021-09-30 | $483.13M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $258.10M 10-Q · filed 2022-11-03 |
| 2021-03-31 | $275.25M 10-Q · filed 2022-08-09 |
| 2020-12-31 | $283.89M 10-K · filed 2024-02-22 |
| 2020-09-30 | $294.69M 10-Q · filed 2021-11-10 |
| 2020-06-30 | -$107.29M 10-Q · filed 2021-11-10 |
| 2020-03-31 | -$93.80M 10-Q · filed 2021-08-06 |
| 2019-12-31 | -$74.41M 10-K · filed 2023-02-23 |
| 2019-09-30 | -$63.22M 10-Q · filed 2020-11-05 |
| 2019-06-30 | -$52.08M 10-Q · filed 2020-11-05 |
| 2018-12-31 | -$34.44M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |